Tipifarnib in hematologic malignancies

Published: June 3, 2009
Abstract Views: 136
PDF: 274
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

I. Rationale for using Tipifarnib in hematologic malignancies Signal transduction pathways regulate the cell processes of growth differentiation and survival. Aberrations in signal transduction pathways can lead to increased cell proliferation, apoptosis inhibition, increased angiogenesis, tissue invasion and metastasis. Most human neoplasias have aberrant signal transduction elements. Therefore signal transduction inhibitors represent a new class of compounds potentially active in cancer treatment. These agents target proteins or pathways that are involved in the pathogenesis of malignancies.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Supporting Agencies

How to Cite

Harousseau, J.-L. (2009). Tipifarnib in hematologic malignancies. Hematology Meeting Reports (formerly Haematologica Reports), 1(8). https://doi.org/10.4081/hmr.v1i8.293